Skip to main content
Premium Trial:

Request an Annual Quote

MDS Files to Buy Back More Shares

NEW YORK (GenomeWeb News) – MDS said today that it has notified the Toronto Stock Exchange that it may purchase up to roughly 5 percent of the float of its public stock on the TSE and New York Stock Exchange during the next year.

The Toronto-based firm said that during the 12 months commencing July 3, 2008, and ending July 2, 2009, it may purchase up to 4,136,766 MDS common shares on the two exchanges.

As of June 20, MDS said there were around 122 million common shares issued and outstanding and 82.7 million common shares in the public float. MDS said that all shares purchased by the firm under the “normal course issuer bid” will be promptly cancelled. It noted that its daily purchases will be limited to 130,250 common shares, other than block purchase exceptions.

During the past year, MDS purchased and cancelled 1.2 million common shares under a previous normal course issuer bid.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.